FDA – OTAT Town Hall: Cell Therapy Chemistry, Manufacturing, and Controls (Cell and Gene Therapy Catapult – Regulatory Round-up – October 2022)
On the 7th of December 2022, the FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) is hosting a virtual town hall to answer stakeholder questions related to cell therapy chemistry, manufacturing, and controls (CMC), including tissue-engineered medical products regulated by OTAT. This event is part of a series to answer questions from stakeholders about a variety of topics on which OTAT has regulatory oversight.
Please find details of this webinar here and the recording of the first event held on the 29th of September 2022 here.
See all of Catapult’s Regulatory Round-up for October 2022 here. Published on the 7th of November 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (25 janvier 2023). FDA – OTAT Town Hall: Cell Therapy Chemistry, Manufacturing, and Controls (Cell and Gene Therapy Catapult – Regulatory Round-up – October 2022). ELSIBI. Consulté le 18 février 2025 à l’adresse https://doi.org/10.58079/o676